Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIND study
2021-005927-19Phase 4Active
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Switch to Biktarvy with Continue Dovato (2 arms). Primary endpoint: Proportion of grade 2-4 neuropsychiatric adverse effects. Started Mar 2022; status: active.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidedolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2021-005927-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005927-19.